

# Bacterial curli protein promotes the conversion of PAP<sub>248–286</sub> into the amyloid SEVI: cross-seeding of dissimilar amyloid sequences

Kevin Hartman<sup>1,2</sup>, Jeffrey R. Brender<sup>1,2</sup>, Kazuaki Monde<sup>3,5</sup>, Akira Ono<sup>3</sup>, Margery L. Evans<sup>4</sup>, Nataliya Popovych<sup>1,2,6</sup>, Matthew R. Chapman<sup>4</sup> and Ayyalusamy Ramamoorthy<sup>1,2</sup>

<sup>1</sup> Department of Chemistry, University of Michigan, USA

<sup>2</sup> Department of Biophysics, University of Michigan, USA

<sup>3</sup> Department of Microbiology and Immunology, University of Michigan Medical School, USA

<sup>4</sup> Department of Molecular, Cellular, and Developmental Biology, University of Michigan, USA

<sup>5</sup> Present address: Department of Medical Virology, Faculty of Life Sciences, Kumamoto University, Japan

<sup>6</sup> Present address: Genentech, USA

## ABSTRACT

Fragments of prostatic acid phosphatase (PAP<sub>248–286</sub>) in human semen dramatically increase HIV infection efficiency by increasing virus adhesion to target cells. PAP<sub>248–286</sub> only enhances HIV infection in the form of amyloid aggregates termed SEVI (Semen Enhancer of Viral Infection), however monomeric PAP<sub>248–286</sub> aggregates very slowly in isolation. It has therefore been suggested that SEVI fiber formation in vivo may be promoted by exogenous factors. We show here that a bacterially-produced extracellular amyloid (curli or Csg) acts as a catalytic agent for SEVI formation from PAP<sub>248–286</sub> at low concentrations in vitro, producing fibers that retain the ability to enhance HIV (Human Immunodeficiency Virus) infection. Kinetic analysis of the cross-seeding effect shows an unusual pattern. Cross-seeding PAP<sub>248–286</sub> with curli only moderately affects the nucleation rate while significantly enhancing the growth of fibers from existing nuclei. This pattern is in contrast to most previous observations of cross-seeding, which show cross-seeding partially bypasses the nucleation step but has little effect on fiber elongation. Seeding other amyloidogenic proteins (IAPP (islet amyloid polypeptide) and A $\beta$ <sub>1–40</sub>) with curli showed varied results. Curli cross-seeding decreased the lag-time of IAPP amyloid formation but strongly inhibited IAPP elongation. Curli cross-seeding exerted a complicated concentration dependent effect on A $\beta$ <sub>1–40</sub> fibrillogenesis kinetics. Combined, these results suggest that the interaction of amyloidogenic proteins with preformed fibers of a different type can take a variety of forms and is not limited to epitaxial nucleation between proteins of similar sequence. The ability of curli fibers to interact with proteins of dissimilar sequences suggests cross-seeding may be a more general phenomenon than previously supposed.

Submitted 14 November 2012

Accepted 5 December 2012

Published 12 February 2013

Corresponding author

Ayyalusamy Ramamoorthy,  
ramamoor@umich.edu

Academic editor

Annalisa Pastore

Additional Information and  
Declarations can be found on  
page 13

DOI 10.7717/peerj.5

© Copyright

2013 Hartman et al.

Distributed under

Creative Commons CC-BY 3.0

OPEN ACCESS

**Subjects** Biochemistry, Biophysics

**Keywords** Functional amyloid, Strain, Kinetics, Seeding, HIV

## INTRODUCTION

Over 33 million people worldwide are currently infected with the HIV virus. While HIV is readily transmitted *in vivo*, HIV is a surprisingly ineffective pathogen *in vitro* (Thomas, Ott & Gorelick, 2007). The key barrier to effective viral transmission is attachment to the target cell surface. The short-half life of almost all viruses in solution (~6 h for HIV) ensures that infection can only be achieved only if a significant number of viral particles adhere to the cell surface in a relatively narrow time window upon exposure (Perelson *et al.*, 1996). A peptide fragment naturally occurring in human seminal fluid (PAP<sub>248–286</sub>) facilitates this first step, and in doing so, greatly enhances the infectivity of HIV (Munch *et al.*, 2007). When fibrillized into amyloid fibers termed SEVI (Semen-derived Enhancer of Virus Infection), (Munch *et al.*, 2007; Arnold *et al.*, 2012; Roan *et al.*, 2011) PAP<sub>248–286</sub> bridges the membranes of the HIV virion and target cells (Munch *et al.*, 2007; Roan *et al.*, 2009; Roan *et al.*, 2010; Wurm *et al.*, 2010; Kim *et al.*, 2010). The result is a dramatic increase in the infectivity of the HIV virus. While up to 100,000 HIV virions are required to establish infection in the absence of SEVI amyloid fibers, only 3 are needed in its presence (Munch *et al.*, 2007).

This enhancement is specifically linked to the SEVI amyloid conformation of PAP<sub>248–286</sub> as monomers of PAP<sub>248–286</sub> have little effect (Munch *et al.*, 2007; Roan *et al.*, 2010; Capule *et al.*, 2012; Olsen *et al.*, 2010). Since PAP<sub>248–286</sub> only enhances HIV infection when in the aggregated SEVI amyloid form, molecules that initiate fibrillization of PAP<sub>248–286</sub> can indirectly increase HIV infectivity. While amyloid formation is typically energetically favorable, the actual rate of formation can be very slow. Specifically, amyloid formation is a nucleation-dependent process in which a slow rate-limiting nucleation step is followed by the faster process of extension of the fiber from the nuclei. PAP<sub>248–286</sub> is subject to significant proteolytic degradation in seminal plasma unless it is in the SEVI amyloid form (Martellini *et al.*, 2011). The total production of SEVI is therefore ultimately controlled by the rate of amyloidosis due to the proteolytic degradation of unfibrillized PAP<sub>248–286</sub>. PAP<sub>248–286</sub> is very slow to fibrillize in the absence of shaking *in vitro*, (Ye *et al.*, 2009; Olsen *et al.*, 2012) which suggests SEVI production will be very limited *in vivo*. Nevertheless, the SEVI amyloid form is found in semen at concentrations of up to 35 µg/mL (Munch *et al.*, 2007; Kim *et al.*, 2010). This finding suggests additional cofactors may be present that accelerate SEVI formation from PAP<sub>248–286</sub> before the PAP<sub>248–286</sub> monomer is degraded by the cell's proteolytic machinery (Olsen *et al.*, 2012).

One set of likely cofactors are other cellular proteins, since the factors that drive self-association of amyloidogenic proteins also tend to favor promiscuous binding to a variety of other proteins (Olzscha *et al.*, 2011; Manzoni *et al.*, 2011). In particular, amyloidogenic proteins frequently have the ability to cross-polymerize, that is amyloid fibers from one protein can catalyze the formation of amyloid fibers from another amyloidogenic protein. Cross-seeding amyloid fibrillogenesis in this manner can dramatically enhance the kinetics of amyloid formation by providing preformed nuclei for further aggregation. Furthermore, the final amyloid fiber can in some cases take on some of

the characteristics of fibers from the initial seeding amyloid protein (*Dzwolak et al., 2005; Foo et al., 2011; Cloe et al., 2011*).

Amyloid nucleation is often considered a highly specific process dependent on a high degree of similarity in both peptide sequence and fiber morphology between the seed and the protein being nucleated. This conclusion has largely been motivated by research on prion amyloid fibers, where the inability of highly homologous prions to cross-seed amyloid formation presents an inter-species barrier to prion transmission (*Chien, Weissman & DePace, 2004; Apostol et al., 2011*). However, this view has recently been challenged by the observation of efficient cross-polymerization between several non-prion amyloid species (*Yagi et al., 2005; Han, Weinreb & Lansbury, 1995; Westermark, Lundmark & Westermark, 2009; Morales et al., 2010; O’Nuallain et al., 2004; Ma & Nussinov, 2012*). Seeds formed from amyloid fibers of some non-homologous proteins can either reduce or eliminate the lag-time of amyloid formation of another protein, (*Yagi et al., 2005; Han, Weinreb & Lansbury, 1995; Westermark, Lundmark & Westermark, 2009; Morales et al., 2010; O’Nuallain et al., 2004; MacPhee & Dobson, 2000*) although the phenomenon is not universal and even single point mutations have been shown to disrupt cross-seeding in some cases (*O’Nuallain et al., 2004; Jarrett & Lansbury, 1992; Hinz, Gierasch & Ignatova, 2008; Rajan et al., 2001*). Cross-seeding may also be asymmetric, with one protein able to seed another but not be seeded by it (*Yu et al., 2012; Siddiqua et al., 2012*).

The amyloids produced by many bacteria and fungi are of particular interest in considering possible cross-seeding reactions with PAP<sub>248–286</sub> because of the high incidence of microbial infection in the vagina and the frequent coexistence with bacterial and fungal infection with HIV infection (*Thurman & Doncel, 2010*). A particularly well studied example is a highly amyloidogenic protein secreted by *Escherichia coli* (E. Coli) and related bacteria, CsgA, that polymerizes into curli fibers that are involved in cell-to-cell and cell-to-surface interactions (*Jordal et al., 2009; Barnhart & Chapman, 2006*). Although curli fibers have not to our knowledge been directly detected so far in semen or the vagina, curli and curli-like amyloid fibers are ubiquitous in mammalian hosts (*Cegelski et al., 2009*). In fact, the innate immune response invoked by almost all amyloids has been proposed to have evolved as a response to curli amyloid formation by E. Coli (*Tukel et al., 2009*). Since functional amyloid fibers from bacteria or yeast similar to curli may be colocalized with PAP<sub>248–286</sub> at the initial site of HIV infection, we tested the effect of preformed curli amyloid fibrils on the kinetics of SEVI fiber formation. We found curli does significantly enhance the rate of SEVI fibrillization, although through an unusual mechanism for a cross-seeding interaction.

## METHODS & MATERIALS

### Peptide preparation

PAP<sub>248–286</sub> was obtained from Biomatik Corporation. To prepare monomeric PAP<sub>248–286</sub>, lyophilized PAP<sub>248–286</sub> was first quickly dissolved in 20% acetic acid to a final concentration of 1 mg/ml to remove preformed aggregates. The aggregate free solution was then

lyophilized overnight. A 3 mg/ml stock solution was made from the lyophilized peptide in the assay buffer (10 mM phosphate buffer, pH 7.3 containing 150 mM NaCl).

Human IAPP was obtained from Genscript. Monomeric IAPP was prepared by first dissolving in hexafluoroisopropanol to a concentration of 1 mg/ml then lyophilizing overnight.  $A\beta_{1-40}$  was obtained from Anaspec. Monomeric  $A\beta_{1-40}$  was prepared in a similar way using 2% ammonium hydroxide instead of hexafluoroisopropanol. The lyophilized pellet of both peptides was dissolved directly in the assay buffer.

### CsgA and CsgB preparation

CsgA and CsgB were expressed ([Hammer, Schmidt & Chapman, 2007](#)) and purified ([Wang et al., 2007](#)) as previously described. Briefly, both were overexpressed as His-tag fusion proteins in LSR12 bacteria. Following centrifugation for 20 min at  $5000 \times g$ , the bacterial pellet was incubated in 8 M guanidine hydrochloride (from Sigma, adjusted to pH 7.2 by the addition of NaOH) for 24 h with stirring. After incubation, the cells were centrifuged again for 20 min at  $10,000 \times g$  and the supernatant sonicated. The solution was then passed over a HIS-Select<sup>TM</sup> HF nickel-nitrilotriacetic acid column, washing first with 50 mM KPi (pH 7.3) followed by 12.5 mM imidazole in 50 mM KPi (pH 7.3) to remove non-specifically bound proteins and then with 125 mM imidazole in 50 mM KPi (pH 7.3) to elute CsgA or CsgB.

To prepare amyloid fibers of CsgA and B, the curli containing fractions from the HIS-Select<sup>TM</sup> column allowed to fibrillize overnight at room temperature. Protein concentration was measured by the BCA (Bicinchoninic Acid) assay prior to fibrillization. The resulting fibers were then centrifuged (15 min at  $10,000 \times g$ ) and washed with water to remove the imidazole salt. This procedure was repeated four times and the pellet then lyophilized. The lyophilized pellets were then reconstituted in the assay buffer and sonicated with a probe sonicator (Sonic Dismembrator Model 100, Fischer Scientific) for approximately 1 min prior to the aggregation assay.

### Aggregation assays

Aggregation assays for PAP<sub>248-286</sub> were performed in 10 mM phosphate buffer, pH 7.3 containing 150 mM NaCl. A total volume of 40  $\mu$ L was placed in each well of a 96 well half area plate with a clear bottom, with 2 mg/mL PAP<sub>248-286</sub>, 25  $\mu$ M Thioflavin T, and either 0, 1, 2.5, or 5 mol% preformed fibers of curli A or B. Aggregation assays for IAPP and  $A\beta_{1-40}$  were performed similarly except different concentrations of peptide (2.5  $\mu$ M of IAPP and 5  $\mu$ M  $A\beta_{1-40}$ ) and CsgA and CsgB were used and the temperature for IAPP aggregation was set to 25 °C. Amyloid fibers of  $A\beta_{1-40}$  and IAPP were prepared by aggregation for 2 days at 37 °C as detailed below and were sonicated for 1 min before loading onto the plate for the seeding experiments.

A single 1 mm glass bead was placed in each well to increase the aggregation rate and promote sample reproducibility ([Giehm & Otzen, 2010](#)). The loaded plate was sealed, and placed on a BioTek Synergy 2 plate reader set at 37 °C (PAP<sub>248-286</sub> and  $A\beta_{1-40}$ ) or 25 °C (IAPP) with a constant linear shaking speed of 17 Hz. Absorbance was monitored at 350 nm and THT fluorescence measurements were taken with an excitation filter at 440 nm

with a bandwidth of 30 nm and an emission filter at 485 nm with a bandwidth of 20 nm. Data points were collected every 10 min, with continual shaking occurring between data points. All experiments were performed with samples in triplicate. The kinetic curves were fitted to a sigmoidal growth model that has empirically been found to reproduce most of the features of amyloid aggregation:

$$I = \frac{I_{\max} - I_0}{1 + e^{(t-t_{1/2})/k}} \quad (1)$$

where  $I_0$  and  $I_{\max}$  are the initial and maximum fluorescence or absorbance values,  $t_{1/2}$  is the time required to reach half intensity, and the elongation time  $t_e$  is an apparent first order time constant for the addition of peptide to existing fibers (Naiki *et al.*, 1991). The lag-time  $t_0$  before detectable aggregation occurs is described by  $t_0 = t_{1/2} - 2t_e$ .

### Transmission electron microscopy


Samples of 6  $\mu\text{L}$  of PAP<sub>248–286</sub> solutions after the aggregation experiment were applied to 200 mesh carbon coated copper electron microscopy grids and allowed to stand for 2 min. The grids were then washed with water 20 times to remove salts, after which 6  $\mu\text{L}$  of a 2% uranyl acetate solution was added and allowed to set for 1 min before being removed. Fiber images were taken on a Phillips X-100 Transmission Electron Microscope operating at 60 kV and 10,500 $\times$  magnification.

### Cells for infectivity assays

A CEM-GFP cell line that expresses a green fluorescent protein (GFP) driven by the HIV-1 LTR promoter was obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH from Dr. Jacques Corbeil and maintained in RPMI1640 (Invitrogen) medium supplemented with 10% heat-inactivated fetal bovine serum (HyClone) (RPMI-10) and containing 500  $\mu\text{g}/\text{ml}$  geneticin (Invitrogen) (Gervaix *et al.*, 1997).

### Infectivity assays

Infectivity assays were performed as previously described (Ono, Monde & Chukkapalli, 2011). A viral stock solution was prepared by transfection of HeLa cells with a HIV-1 molecular clone pNL4-3. Supernatants of transfected cells were collected 2 days post-transfection, and viruses in the supernatant solution were pelleted by ultracentrifugation and resuspended in RPMI-10 medium. These virus stocks (20,000 cpm RT activity) were combined with stock solutions of SEVI amyloid fibers (50  $\mu\text{g}/\text{ml}$  from a stock solution of 440  $\mu\text{M}$  PAP<sub>248–286</sub> incubated under aseptic conditions for 7 days at 37 °C under vigorous agitation (1300 rpm)) and used to inoculate  $2 \times 10^5$  of CEM-GFP in 100  $\mu\text{L}$  RPMI-10 for 2 h at 37 °C. Cells were then washed and incubated in 1 ml RPMI-10 at 37 °C. Inoculations were performed in triplicate. To block the second round of infection, the CD4 blocking antibody Leu3a (0.25  $\mu\text{g}/\text{ml}$ ) (BD Biosciences) and the reverse transcriptase inhibitor AZT (1  $\mu\text{M}$ ) (Sigma) were added to the medium 12 h post-infection. Two days post-infection, cells were fixed in 4% paraformaldehyde in PBS (phosphate buffer



**Figure 1** Kinetics of SEVI amyloid fiber formation in the presence of preformed fibers of CsgA and CsgB. Top: Turbidity measurements at 350 nm (A) PAP<sub>248–286</sub> + CsgA, (B) PAP<sub>248–286</sub> + CsgB. Bottom: ThT fluorescence measurements of (C) PAP<sub>248–286</sub> + CsgA, (D) PAP<sub>248–286</sub> + Csg B. Curves are averages for 3 measurements.


saline) and analyzed using a FACSCanto flow cytometer and the FlowJo software ver. 8.7.1. Efficiencies of infection were determined directly from the percentage of GFP positive cells after subtraction of the baseline activity obtained in the absence of HIV-1<sub>NL4–3</sub>. Comparisons between samples were made using a one-tailed unpaired Student t-test.

## RESULTS

### Seeding with curli fibers greatly increases the rate of SEVI formation from PAP<sub>248–286</sub>

To test the *in vitro* activity of curli on the kinetics of SEVI amyloid formation from PAP<sub>248–286</sub>, we measured the kinetics of amyloid formation and aggregation of 440 μM PAP<sub>248–286</sub> solutions in the presence of curli nuclei (Giehm & Otzen, 2010). The curli amyloid fiber is actually a composite of several proteins, (Barnhart & Chapman, 2006) with CsgA serving as the main structural scaffold and CsgB nucleating amyloid formation from CsgA (sequences given in Fig. S1) (Wang, Hammer & Chapman, 2008).


PAP<sub>248–286</sub> aggregated slowly in the absence of preformed nuclei of any type under the conditions tested (Olsen et al., 2012), as shown by both turbidity measurements (a nonspecific indicator of general aggregation, Figs. 1C and 1D) and ThT fluorescence (a measurement specific for amyloid, Figs. 1A and 1B). The lag time of formation (~60 h) is considerably longer than that previously described (~18 h), (Munch et al., 2007; Ye et al., 2009) at an identical concentration, most likely due to a difference in shaking speed or ionic strength (Olsen et al., 2012).



**Figure 2** Elongation of SEVI amyloid fibers is significantly enhanced by preformed fibers of CsgA and CsgB lag time is less affected. Impact of preformed curli A and B fibers on the lag time (A and C) and elongation time (B and D) of SEVI formation. (A and B): Kinetic constants as determined by ThT fluorescence. (C and D): Kinetic constants as determined by turbidity measurements. Error bars represent S.E.M.

Turbidity increased before ThT fluorescence for samples without CsgA or CsgB (Fig. 1). In addition, while the changes in turbidity could be closely approximated by a sigmoidal curve for all samples, analysis of the residuals from the sigmoidal fit to the ThT fluorescence shows two additional features not present in the turbidity curves. First, a second early component with a short lag time (about 18 h, similar to previous observations (Munch et al., 2007; Ye et al., 2009)) but low ThT fluorescence (about 1/8 of the final value) can be detected in the ThT measurements. Second, ThT fluorescence immediately decreases after the addition of high concentrations of CsgA. These findings suggest amyloid formation by PAP<sub>248–286</sub> may be a multistep process in which either the formation of non-amyloid prefibrillar aggregates occurs before amyloid formation for these samples (Suzuki et al., 2012; Horvath et al., 2012) or bundling of amyloid-like protofibrillar filaments is necessary for ThT binding to SEVI, as has been observed for other amyloidogenic proteins (Cabaleiro-Lago et al., 2010).

The addition of preformed CsgA seed had a dramatic impact on the kinetics of SEVI amyloid formation. One mol% CsgA (relative to PAP<sub>248–286</sub>) was sufficient to cause a six-fold decrease in the elongation time constant, which is reflective of the time for the addition of PAP<sub>248–286</sub> to existing fibers (Fig. 2B). CsgA seeds had only a minor effect on the lag time (Figs. 2A and 2C). This is an unexpected result, as the addition of seeds usually results in the reduction or elimination of the lag-time with



**Figure 3** Curli nucleation produces longer SEVI fibers. Top: TEM images of SEVI fibers formed in the absence of curli (A) and in the presence of 5 mol% CsgA (B) and CsgB (C) fibers. Bottom: TEM images of CsgA (D) and CsgB (E) fibers. (F) Aspect ratios of individual fibers grown with and without curli nucleation ( $n = 47, 23$  and  $37$  for SEVI, SEVI+ CsgA, and SEVI+ CsgB respectively). Fibers were grown at a concentration of  $440 \mu\text{M}$  PAP<sub>248–286</sub> at  $37^\circ\text{C}$  under  $1400$  rpm orbital shaking for 7 days. P values were determined using a two-tailed unpaired Student t-test against the control sample.


little corresponding change in the rate of addition to pre-existing fibers (Yagi *et al.*, 2005). CsgB has qualitatively similar effects as CsgA on the kinetics of SEVI amyloid formation, however the magnitude of the effect is relatively less in comparison to CsgA (Figs. 1 and 2).

The difference in elongation rates for Csg initiated PAP<sub>248–286</sub> fiber formation is reflected in the morphology of individual fibers. Fibers samples initiated by curli and those grown in their absence are morphologically similar, except for a large difference in the aspect ratios (Figs. 3A–3C and Fig. S2). Standard SEVI fibers have an aspect ratio of approximately 5.8, while those grown with CsgA and CsgB are more heterogeneous and much longer, with aspect ratios of approximately 14.7 and 10.8 respectively (Fig. 3F and Fig. S2). This finding is in agreement with the greatly enhanced fiber elongation rate found in the presence of either of the curli fibers. The very short and broken fibers of all PAP<sub>248–286</sub> samples are different than typical amyloid fibers, such as the CsgA and CsgB fibers formed under quiescent conditions (Figs. 3D and 3E), most likely because the high degree of agitation required for SEVI fiber formation fragments nascent amyloid fibers.

### SEVI amyloid fibers obtained from curli nucleation retain the ability to enhance HIV infection

We next confirmed that curli nucleated SEVI fiber samples retain a similar ability to promote HIV infection as SEVI fibers generated *de novo*. The activity of the SEVI fibrils incubated with Csg was tested using an infectivity assay in which a reporter T cell line that expresses GFP upon HIV infection was used (Gervaix *et al.*, 1997). In the absence






**Figure 4** Curli nucleated SEVI fibers enhance HIV infectivity to a similar degree as SEVI generated *de novo*. CEM-GFP cells were infected with HIV-1<sub>NL4-3</sub> (20,000 cpm RT activity) supplemented either with 50  $\mu$ g/ml of the proteins indicated or PBS (phosphate buffered saline). SEVI samples were fibrillized for 7 days prior to infection. Measurements were performed in triplicate, error bars indicate S.E.M. P values were determined using a two-tailed unpaired Student t-test against the control sample.

of SEVI, flow cytometry showed a low percentage of GFP-positive cells, in agreement with the low infectivity of HIV under the conditions employed. The addition of SEVI fibrils generated *de novo* caused an approximately 8-fold increase in the infectivity (Fig. 4), roughly matching results of other studies of SEVI under conditions of high viral load (Roan *et al.*, 2009; Roan *et al.*, 2010; Hauber *et al.*, 2009). The much larger degree of enhancement shown in some studies (>100,000 times) is only apparent at very high viral dilution (Munch *et al.*, 2007). Neither the PAP<sub>248-286</sub> monomer nor equivalent amounts of CsgA or CsgB alone had an effect on HIV infection efficiency (Fig. 4). On the other hand, CsgA and CsgB nucleated fibers enhanced HIV infection at least to the same extent as *de novo* generated SEVI fibers (13 and 16 times respectively, Fig. 4). From these results, it can be seen that the SEVI fiber samples, regardless of how they were nucleated, show a comparable ability to enhance the rate of HIV infection.

### Cross-seeding with curli at low concentrations affects the amyloidogenesis of other proteins besides PAP<sub>248-286</sub>

The ability of curli to accelerate SEVI formation in the absence of any obvious sequence similarity suggests curli may accelerate amyloid formation by other proteins as well. To test this possibility, we performed analogous seeding experiments on the amyloidogenic peptides IAPP and A $\beta$ <sub>1-40</sub>. Addition of preformed curli nuclei had a complex effect on the aggregation of both these peptides (Fig. 5 and Fig. S3). The fibrillization rate of IAPP was strongly decreased by low concentrations of both CsgA and Csg B (1% of the IAPP concentration or 25 nM) (Fig. 5). Addition of CsgA, but not CsgB, to IAPP also lowered



**Figure 5** Curli's ability to influence amyloid formation is not limited to PAP<sub>248–286</sub>. Impact of preformed csgA and csgB fibers on the lag time (A and C) and elongation time (B and D) of amyloid formation from 2.5 μM IAPP (top) and 5 μM Aβ<sub>1–40</sub> (bottom) as molar fractions of the IAPP and Aβ<sub>1–40</sub> concentrations.

the total ThT fluorescence, suggesting either fewer or shorter fibers are produced in the presence of CsgA. The effect of CsgA and CsgB on the fibrillization rate of Aβ<sub>1–40</sub> was more modest, and showed a more complex dependence on the concentration with the fibrillization rate slightly decreasing at lower concentrations and slightly increasing at higher concentrations of both CsgA and CsgB (Fig. 5). The lag time of both peptides decreased by approximately 50% after addition of 10 mol% of the oppositely charged Csg protein (CsgA for IAPP and CsgB for Aβ<sub>1–40</sub>), smaller amounts had little effect. Addition of 1% of the similarly charged Csg protein increased the lag time of both peptides, surprisingly, larger amounts had little effect on the lag time. By comparison, addition of equivalent amounts of preformed Aβ<sub>1–40</sub> fibril seeds led to a linear decrease in induction time but had little effect on the fibrillization rate (Fig. S4). Although a complete characterization of curli with IAPP and Aβ<sub>1–40</sub> lies outside the scope of this study, it can be seen from these experiments that both the effect of curli nucleation on amyloid fibrillogenesis is not limited to PAP<sub>248–286</sub> and that curli can serve as both an inhibitor and enhancer of fibrillization.


## DISCUSSION

In this study, we characterized the kinetics of PAP<sub>248–286</sub> cross-seeded by the curli proteins CsgA and CsgB in comparison to the analogous cross-seeding interactions with the more amyloidogenic proteins hIAPP and Aβ<sub>1–40</sub>. The purpose of this experiment is two-fold. First, PAP<sub>248–286</sub> is only biologically active in the SEVI amyloid fiber form. The production of these fibers is ultimately controlled by the rate of amyloidogenesis, as PAP<sub>248–286</sub> is

subject to inactivating proteolysis in its monomeric but not in its amyloid form (*Martellini et al., 2011*). Since SEVI fibers have been detected in semen under conditions that would apparently not easily allow aggregation *in vitro* of SEVI alone, (*Munch et al., 2007; Kim et al., 2010*) extrinsic factors are a likely source to look for influences on PAP<sub>248–286</sub> aggregation. Second, amyloid cross-seeding as a general phenomenon is not well understood, as apparently contradictory results regarding the efficiency and specificity of cross-seeding have been obtained (*Yagi et al., 2005; Han, Weinreb & Lansbury, 1995; Westermark, Lundmark & Westermark, 2009; Morales et al., 2010; O’Nuallain et al., 2004; MacPhee & Dobson, 2000; Jarrett & Lansbury, 1992; Hinz, Gierasch & Ignatova, 2008; Rajan et al., 2001*). In performing the cross-seeding of PAP<sub>248–286</sub>, we found that while the lag-time for amyloid formation is moderately affected by curli seeding, the elongation rate is greatly increased. This finding is novel for a cross-seeding reaction and is discussed in more depth below.

An understanding of this result requires some knowledge of the basic mechanism of the cross-seeding reaction. In epitaxial heteronucleation, growth occurs by specific structural matching of the seeding nucleus with the protein being seeded (*Fig. 6*) (*Apostol et al., 2011; Wasmer et al., 2010*). A greater understanding of this process can be made by considering the structural constraints for amyloid formation. The cross  $\beta$ -sheet structure common to all amyloids is built by the intermolecular association of  $\beta$  sheets that are stabilized by hydrogen bonds between amide backbone atoms of adjacent sheets. Since the amide backbone, in contrast to the side-chain residues, is similar in all proteins, any unfolded or partially folded protein should theoretically be able to associate with preformed seeds of another to form mixed fibers. However, amyloid fibers apparently derive much of their energy from the formation of a “steric zipper”, in which the sidechains from adjacent sheets form an interlocking dry surface (*Apostol et al., 2011; Sawaya et al., 2007; Eisenberg et al., 2011; Colletier et al., 2011*). It can be seen from this requirement that epitaxial heteronucleation is unlikely to occur if the seeding nucleus is structurally different than the protein being seeded, (*Apostol et al., 2011; Wasmer et al., 2010; Wiltzius et al., 2009*) consistent with the observation that cross-seeding between amyloid proteins is most efficient when the two proteins have homologous sequences (*Krebs et al., 2004*). For most amyloidogenic proteins this requirement is quite strict and even single point mutations can eliminate the ability of one amyloidogenic protein to cross-seed another. For others, the best studied being  $\alpha$ -synuclein which seeds a variety of non-homologous proteins, this requirement is relaxed, possibly because the disorder present in the  $\alpha$ -synuclein’s fiber structure can accommodate multiple fiber polymorphs and different fiber interfaces (*Yagi et al., 2005*).

In the simplest model of epitaxially nucleated amyloidogenesis, the elongation time decreases linearly with the concentration of the seed as each new seed provides a new point of fibril growth (*Padrick & Miranker, 2002; Cohen et al., 2011*). However, the elongation time is less sensitive to the seed concentration in more complicated models explicitly considering secondary nucleation by fragmentation of existing fibers, as the new fibers created by fragmentation provide additional points for fibril growth that compete with the



**Figure 6** Cartoon models of possible cross-seeding reactions. Top: Epitaxial Heteronucleation (A) Binding of the PAP<sub>248–286</sub> monomer (red) to the curli seed (blue) induces formation of the  $\beta$ -sheet conformation of PAP<sub>248–286</sub> (B) Fiber growth proceeds epitaxially from the seeding nucleus Bottom: Possible mechanism for non-epitaxial heteronucleation (C) A nucleus for the SEVI fiber forms independently of the curli fiber (D) Growth of the SEVI fiber initially proceeds slowly due to unfavorable interactions between subunits of the fiber (E) Lateral attachment of the nascent SEVI fiber to curli reduces repulsion between fiber subunits thereby enhancing the rate of fibrillogenesis. The curli seed may be incorporated into the final SEVI fiber or may detach to catalyze further fiber extension events.

nuclei from the original seeds (Cohen *et al.*, 2011; Knowles *et al.*, 2009). The maximal elongation rate is in fact relatively insensitive to the seeding concentration when the number of nuclei created by fibril fragmentation is much greater than the number of nuclei available from seeding (Cohen *et al.*, 2011; Knowles *et al.*, 2009). Such behavior is typically observed experimentally (Yagi *et al.*, 2005; Han, Weinreb & Lansbury, 1995; Padrick & Miranker, 2002; Xue, Homans & Radford, 2008) and is seen here with the A $\beta$ <sub>1–40</sub> protein (see Fig. S4). Regardless of the exact quantitative expression, current models predict that the lag-time for epitaxial heteronucleation should be more strongly affected than the elongation time.

However, epitaxial heteronucleation is not the only possible mechanism by which cross-seeding can occur. In contrast to epitaxial heteronucleation, non-specific heteronucleation can affect both the lag-time and the elongation rate by affecting the stability of different species along the aggregation pathway or by lowering the surface tension associated with forming clusters of the protein. In these mechanisms, the seed is not necessarily incorporated into the new amyloid fiber. Non-specific heteronucleation has been proposed for surfaces and non-protein ligands, (Pronchik *et al.*, 2010; Auer, Trovato & Vendruscolo, 2009; Yin, Chen & Liu, 2009) but not to our knowledge for cross-seeding reactions with other amyloidogenic proteins. Experiments with Lys to Ala PAP<sub>248–286</sub> mutants show that charge repulsion between monomer units destabilizes the amyloid fiber (Roan *et al.*, 2009). Lateral association of the curli fiber with the nascent PAP<sub>248–286</sub> fiber can reduce this repulsion between monomer subunits, increasing the elongation rate but not affecting the lag-time. In this case, it is expected that the electrostatic differences between CsgA and CsgB (–6 overall charge for CsgA and +5 for CsgB, PAP<sub>248–286</sub> carries an overall charge of +6) are primarily responsible for the difference in cross-seeding efficiencies, although differences atomic-level differences in the packing between CsgA and CsgB and

PAP<sub>248–286</sub> may also play a role. It is important to note that a stable interaction between the PAP<sub>248–286</sub> amyloid fiber and CsgA or CsgB may not be required, as theoretical studies show that the stability of amyloid fibers increases with the length of the fiber (*Linse & Linse, 2011*). A transient interaction of CsgA or CsgB with PAP<sub>248–286</sub> may stabilize a short, energetically unfavorable PAP<sub>248–286</sub> fiber long enough to promote the formation of a longer and more stable amyloid fiber.

The interaction of curli with IAPP and A $\beta$ <sub>1–40</sub> is less clear. Electrostatics plays a role in cross-seeding nucleation, as the oppositely charged curli protein reduces the lag-time of both IAPP and A $\beta$ <sub>1–40</sub> but the similarly charged curli protein has less effect. Both CsgA and CsgB decrease the elongation rate of IAPP, most likely by binding to and blocking reactive fibril ends. The effect of CsgA and CsgB on the elongation rate of A $\beta$ <sub>1–40</sub> has a complex concentration dependence, likely the result of a mixture of stimulatory and inhibitory effects previously observed in the binding of some ligands to amyloid peptides.

Although the effects of curli on A $\beta$ <sub>1–40</sub> were moderate, cross-seeding between other bacterial functional amyloids and A $\beta$ <sub>1–40</sub> may have greater clinical significance. For example, the bacteria *Borrelia burgdorferi* produces a curli-like amyloid protein that colocalizes with A $\beta$  amyloid deposits in Alzheimer's patients (*Miklossy, 2008; Miklossy et al., 2004*). Similarly, inoculation with *Chlamydia pneumoniae* stimulates the production of A $\beta$ <sub>1–42</sub> amyloid plaques, (*Gerard et al., 2006; Little et al., 2004*) although to our knowledge a curli-like amyloid protein has not been found yet for *Chlamydia pneumoniae*. Although a definitive link between bacterial infection and amyloid-associated neurodegenerative diseases has been elusive due to the difficulties in firmly establishing bacterial infection considering the low levels of bacteria typical of chronic long-term infections (*Dobson, Wozniak & Itzhaki, 2003*) the identification of new amyloidogenic proteins in bacteria and mammals is increasing rapidly (*Jordal et al., 2009*) opening up the possibility of an increasing role for bacterial and viral infections in poorly understood amyloidogenic diseases.

## ACKNOWLEDGEMENTS

The following reagent was obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: CEM-GFP from Jacques Corbeil.

## ADDITIONAL INFORMATION AND DECLARATIONS

### Funding

This study was supported by research funds from the NIH (GM095640 to Ayyalusamy Ramamoorthy; AI089282 to Akira Ono; and AI073847 to Matthew R. Chapman). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

### Grant Disclosures

The following grant information was disclosed by the authors:  
NIH: GM095640, AI089282, AI073847.

## Competing Interests

One of the authors, Ayyalusamy Ramamoorthy, is an Academic Editor for PeerJ.

## Author Contributions

- Kevin Hartman performed the experiments, analyzed the data.
- Jeffrey R. Brender and Ayyalusamy Ramamoorthy conceived and designed the experiments, performed the experiments, analyzed the data, wrote the paper.
- Kazuaki Monde performed the experiments.
- Akira Ono conceived and designed the experiments, analyzed the data, wrote the paper.
- Margery L. Evans and Matthew R. Chapman contributed reagents/materials/analysis tools, made other contributions.
- Nataliya Popovych made other contributions.

## Supplementary Information

Supplemental information for this article can be found online at <http://dx.doi.org/10.7717/peerj.5>.

## REFERENCES

- Apostol MI, Wiltzius JJW, Sawaya MR, Cascio D, Eisenberg D. 2011.** Atomic structures suggest determinants of transmission barriers in mammalian prion disease. *Biochemistry* 50:2456–2463 DOI [10.1021/bi101803k](https://doi.org/10.1021/bi101803k).
- Arnold F, Schnell J, Zirafi O, Sturzel C, Meier C, Weil T, Standker L, Forssmann WG, Roan NR, Greene WC, Kirchhoff F, Munch J. 2012.** Naturally occurring fragments from two distinct regions of the prostatic acid phosphatase form amyloidogenic enhancers of HIV infection. *Journal of Virology* 86:1244–1249 DOI [10.1128/JVI.06121-11](https://doi.org/10.1128/JVI.06121-11).
- Auer S, Trovato A, Vendruscolo M. 2009.** A condensation-ordering mechanism in nanoparticle-catalyzed peptide aggregation. *PLOS Computational Biology* 5:e1000458 DOI [10.1371/journal.pcbi.1000458](https://doi.org/10.1371/journal.pcbi.1000458).
- Barnhart MM, Chapman MR. 2006.** Curli biogenesis and function. *Annual Review Microbiology* 60:131–147 DOI [10.1146/annurev.micro.60.080805.142106](https://doi.org/10.1146/annurev.micro.60.080805.142106).
- Cabaleiro-Lago C, Lynch I, Dawson KA, Linse S. 2010.** Inhibition of IAPP and IAPP((20-29)) fibrillation by polymeric nanoparticles. *Langmuir* 26:3453–3461 DOI [10.1021/la902980d](https://doi.org/10.1021/la902980d).
- Capule CC, Brown C, Olsen JS, Dewhurst S, Yang J. 2012.** Oligovalent amyloid-binding agents reduce SEVI-mediated enhancement of HIV-1 infection. *Journal of American Chemical Society* 134:905–908 DOI [10.1021/ja210931b](https://doi.org/10.1021/ja210931b).
- Cegelski L, Pinkner JS, Hammer ND, Cusumano CK, Hung CS, Chorell E, Aberg V, Walker JN, Seed PC, Almqvist F, Chapman MR, Hultgren SJ. 2009.** Small-molecule inhibitors target *Escherichia coli* amyloid biogenesis and biofilm formation. *Nature Chemical Biology* 5:913–919 DOI [10.1038/nchembio.242](https://doi.org/10.1038/nchembio.242).
- Chien P, Weissman JS, DePace AH. 2004.** Emerging principles of conformation based prion inheritance. *Annual Review Biochemistry* 73:617–656 DOI [10.1146/annurev.biochem.72.121801.161837](https://doi.org/10.1146/annurev.biochem.72.121801.161837).
- Cloe AL, Orgel JPRO, Sachleben JR, Tycko R, Meredith SC. 2011.** The Japanese Mutant A $\beta$  ( $\Delta$ E22-A $\beta$ (1-39)) forms fibrils instantaneously, with low-thioflavin T fluorescence: seeding

- of Wild-Type A $\beta$ (1-40) into atypical fibrils by  $\Delta$ E22-A $\beta$ (1-39). *Biochemistry* **50**:2026–2039 DOI [10.1021/bi1016217](https://doi.org/10.1021/bi1016217).
- Cohen SIA, Vendruscolo M, Dobson CM, Knowles TPJ. 2011.** Nucleated polymerization with secondary pathways. II. Determination of self-consistent solutions to growth processes described by non-linear master equations. *Journal of Chemisry Physics* **135**:065105-1–065105-16.
- Colletier JP, Laganowsky A, Landau M, Zhao ML, Soriaga AB, Goldschmidt L, Flot D, Cascio D, Sawaya MR, Eisenberg D. 2011.** Molecular basis for amyloid-beta polymorphism. *Proceedings of the National Academy of Sciences of the United States of America* **108**:16938–16943 DOI [10.1073/pnas.1112600108](https://doi.org/10.1073/pnas.1112600108).
- Dobson CB, Wozniak MA, Itzhaki RF. 2003.** Do infectious agents play a role in dementia? *Trends Microbiology* **11**:312–317 DOI [10.1016/S0966-842X\(03\)00146-X](https://doi.org/10.1016/S0966-842X(03)00146-X).
- Dzwolak W, Jansen R, Smirnovas V, Lokszejn A, Porowski S, Winter R. 2005.** Template-controlled conformational patterns of insulin fibrillar self-assembly reflect history of solvation of the amyloid nuclei. *Physical Chemistry Chemical Physics* **7**:1349–1351 DOI [10.1039/b502255j](https://doi.org/10.1039/b502255j).
- Eisenberg D, Sievers SA, Karanicolas J, Chang HW, Zhao A, Jiang L, Zirafi O, Stevens JT, Munch J, Baker D. 2011.** Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation. *Nature* **475**:96–U117 DOI [10.1038/nature10154](https://doi.org/10.1038/nature10154).
- Foo CK, Ohhashi Y, Kelly MJS, Tanaka M, Weissman JS. 2011.** Radically different amyloid conformations dictate the seeding specificity of a chimeric Sup35 prion. *Journal of Molecular Biology* **408**:1–8 DOI [10.1016/j.jmb.2011.02.025](https://doi.org/10.1016/j.jmb.2011.02.025).
- Gerard HC, Dreses-Werringloer U, Wildt KS, Deka S, Oszust C, Balin BJ, Frey WH, Bordayo EZ, Whittum-Hudson JA, Hudson AP. 2006.** Chlamydophila (Chlamydia) pneumoniae in the Alzheimer's brain. *FEMS Immunology and Medical Microbiology* **48**:355–366 DOI [10.1111/j.1574-695X.2006.00154.x](https://doi.org/10.1111/j.1574-695X.2006.00154.x).
- Gervaix A, West D, Leoni LM, Richman DD, WongStaal F, Corbeil J. 1997.** A new reporter cell line to monitor HIV infection and drug susceptibility in vitro. *Proceedings of the National Academy of Sciences of the United States of America* **94**:4653–4658 DOI [10.1073/pnas.94.9.4653](https://doi.org/10.1073/pnas.94.9.4653).
- Giehm L, Otzen DE. 2010.** Strategies to increase the reproducibility of protein fibrillization in plate reader assays. *Analytical Biochemistry* **400**:270–281 DOI [10.1016/j.ab.2010.02.001](https://doi.org/10.1016/j.ab.2010.02.001).
- Hammer ND, Schmidt JC, Chapman MR. 2007.** The curli nucleator protein, CsgB, contains an amyloidogenic domain that directs CsgA polymerization. *Proceedings of the National Academy of Sciences of the United States of America* **104**:12494–12499 DOI [10.1073/pnas.0703310104](https://doi.org/10.1073/pnas.0703310104).
- Han HY, Weinreb PH, Lansbury PT. 1995.** The core Alzheimers peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid - Is NAC a common trigger or target in neurodegenerative disease? *Chemical Biology* **2**:163–169 DOI [10.1016/1074-5521\(95\)90071-3](https://doi.org/10.1016/1074-5521(95)90071-3).
- Hauber I, Hohenberg H, Holstermann B, Hunstein W, Hauber J. 2009.** The main green tea polyphenol epigallocatechin-3-gallate counteracts semen-mediated enhancement of HIV infection. *Proceedings of the National Academy of Sciences of the United States of America* **106**:9033–9038 DOI [10.1073/pnas.0811827106](https://doi.org/10.1073/pnas.0811827106).
- Hinz J, Gierasch LM, Ignatova Z. 2008.** Orthogonal cross-seeding: an approach to explore protein aggregates in living cells. *Biochemistry* **47**:4196–4200 DOI [10.1021/bi800002j](https://doi.org/10.1021/bi800002j).
- Horvath I, Weise CF, Andersson EK, Chorell E, Sellstedt M, Bengtsson C, Olofsson A, Hultgren SJ, Chapman M, Wolf-Watz M, Almqvist F, Wittung-Stafshede P. 2012.** Mechanisms of protein oligomerization: inhibitor of functional amyloids templates

- alpha-synuclein fibrillation. *Journal of American Chemical Society* **134**:3439–3444 DOI [10.1021/ja209829m](https://doi.org/10.1021/ja209829m).
- Jarrett JT, Lansbury PT. 1992. Amyloid fibril formation requires a chemically discriminating nucleation event - Studies of an amyloidogenic sequence from the bacterial protein Osmb. *Biochemistry* **31**:12345–12352 DOI [10.1021/bio0164a008](https://doi.org/10.1021/bio0164a008).
- Jordal PB, Dueholm MS, Larsen P, Petersen SV, Enghild JJ, Christiansen G, Hojrup P, Nielsen PH, Otzen DE. 2009. Widespread abundance of functional bacterial amyloid in mycolata and other gram-positive bacteria. *Applied Environmental Microbiology* **75**:4101–4110 DOI [10.1128/AEM.02107-08](https://doi.org/10.1128/AEM.02107-08).
- Kim KA, Yolamanova M, Zirafi O, Roan NR, Standker L, Forssmann WG, Burgener A, Dejuqc-Rainsford N, Hahn BH, Shaw GM, Greene WC, Kirchhoff F, Muench J. 2010. Semen-mediated enhancement of HIV infection is donor-dependent and correlates with the levels of SEVI. *Retrovirology* **7**:55–67 DOI [10.1186/1742-4690-7-55](https://doi.org/10.1186/1742-4690-7-55).
- Knowles TPJ, Waudby CA, Devlin GL, Cohen SIA, Aguzzi A, Vendruscolo M, Terentjev EM, Welland ME, Dobson CM. 2009. An analytical solution to the kinetics of breakable filament assembly. *Science* **326**:1533–1537 DOI [10.1126/science.1178250](https://doi.org/10.1126/science.1178250).
- Krebs MR, Morozova-Roche LA, Daniel K, Robinson CV, Dobson CM. 2004. Observation of sequence specificity in the seeding of protein amyloid fibrils. *Protein Sciences* **13**:1933–1938 DOI [10.1110/ps.04707004](https://doi.org/10.1110/ps.04707004).
- Linse B, Linse S. 2011. Monte Carlo simulations of protein amyloid formation reveal origin of sigmoidal aggregation kinetics. *Molecular Biosystems* **7**:2296–2303 DOI [10.1039/comb00321b](https://doi.org/10.1039/comb00321b).
- Little CS, Hammond CJ, MacIntyre A, Balin BJ, Appelt DM. 2004. Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice. *Neurobiology of Aging* **25**:419–429 DOI [10.1016/S0197-4580\(03\)00127-1](https://doi.org/10.1016/S0197-4580(03)00127-1).
- Ma BY, Nussinov R. 2012. Selective molecular recognition in amyloid growth and transmission and cross-species barriers. *Journal of Molecular Biology* **421**:172–184 DOI [10.1016/j.jmb.2011.11.023](https://doi.org/10.1016/j.jmb.2011.11.023).
- MacPhee CE, Dobson CM. 2000. Formation of mixed fibrils demonstrates the generic nature and potential utility of amyloid nanostructures. *Journal of American Chemical Society* **122**:12707–12713 DOI [10.1021/ja0029580](https://doi.org/10.1021/ja0029580).
- Manzoni C, Colombo L, Bigini P, Diana V, Cagnotto A, Messa M, Lupi M, Bonetto V, Pignataro M, Airoidi C, Sironi E, Williams A, Salmona M. 2011. The molecular assembly of amyloid A $\beta$  controls its neurotoxicity and binding to cellular proteins. *PLOS ONE* **6**:e24909 DOI [10.1371/journal.pone.0024909](https://doi.org/10.1371/journal.pone.0024909).
- Martellini JA, Cole AL, Svoboda P, Stuchlik O, Chen LM, Chai KX, Gangrade BK, Sorensen OE, Pohl J, Cole AM. 2011. HIV-1 enhancing effect of prostatic acid phosphatase peptides is reduced in human seminal plasma. *PLOS ONE* **6**:e16285 DOI [10.1371/journal.pone.0016285](https://doi.org/10.1371/journal.pone.0016285).
- Miklossy J. 2008. Chronic inflammation and amyloidogenesis in Alzheimer's disease - Role of spirochetes. *Journal of Alzheimer's Disease* **13**:381–391.
- Miklossy J, Khalili K, Gern L, Ericson RL, Darekar P, Bolle L, Hurlimann J, Paster BJ. 2004. *Borrelia burgdorferi* persists in the brain in chronic lyme neuroborreliosis and may be associated with Alzheimer disease. *Journal of Alzheimer's Disease* **6**:639–649.
- Morales R, Estrada LD, Diaz-Espinoza R, Morales-Scheihing D, Jara MC, Castilla J, Soto C. 2010. Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases. *Journal of Neuroscience* **30**:4528–4535 DOI [10.1523/JNEUROSCI.5924-09.2010](https://doi.org/10.1523/JNEUROSCI.5924-09.2010).



- Munch J, Rucker E, Standker L, Adermann K, Goffinet C, Schindler M, Wildum S, Chinnadurai R, Rajan D, Specht A, Gimenez-Gallego G, Sanchez PC, Fowler DM, Koulov A, Kelly JW, Mothes W, Grivel JC, Margolis L, Keppler OT, Forssmann WG, Kirchhoff F. 2007. Semen-derived amyloid fibrils drastically enhance HIV infection. *Cell* **131**:1059–1071 DOI [10.1016/j.cell.2007.10.014](https://doi.org/10.1016/j.cell.2007.10.014).
- Naiki H, Higuchi K, Nakakuki K, Takeda T. 1991. Kinetic analysis of amyloid fibril polymerization in vitro. *Laboratory Investigation* **65**:104–110.
- Olsen JS, Brown C, Capule CC, Rubinshtein M, Doran TM, Srivastava RK, Feng C, Nilsson BL, Yang J, Dewhurst S. 2010. Amyloid-binding small molecules efficiently block SEVI (semen-derived enhancer of virus infection)- and semen-mediated enhancement of HIV-1 infection. *Journal of Biological Chemistry* **285**:35488–35496 DOI [10.1074/jbc.M110.163659](https://doi.org/10.1074/jbc.M110.163659).
- Olsen JS, DiMaio JTM, Doran TM, Brown C, Nilsson BL, Dewhurst S. 2012. Seminal Plasma accelerates semen-derived enhancer of viral infection (SEVI) fibril formation by the prostatic acid phosphatase (PAP<sub>(248–286)</sub>) peptide. *Journal of Biological Chemistry* **287**:11842–11849 DOI [10.1074/jbc.M111.314336](https://doi.org/10.1074/jbc.M111.314336).
- Olzscha H, Schermann SM, Woerner AC, Pinkert S, Hecht MH, Tartaglia GG, Vendruscolo M, Hayer-Hartl M, Hartl FU, Vabulas RM. 2011. Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. *Cell* **144**:67–78 DOI [10.1016/j.cell.2010.11.050](https://doi.org/10.1016/j.cell.2010.11.050).
- O’Nuallain B, Williams AD, Westermark P, Wetzel R. 2004. Seeding specificity in amyloid growth induced by heterologous fibrils. *Journal of Biological Chemistry* **279**:17490–17499 DOI [10.1074/jbc.M311300200](https://doi.org/10.1074/jbc.M311300200).
- Ono A, Monde K, Chukkapalli V. 2011. Assembly and replication of HIV-1 in T cells with low levels of phosphatidylinositol-(4,5)-bisphosphate. *Journal of Virology* **85**:3584–3595 DOI [10.1128/JVI.02266-10](https://doi.org/10.1128/JVI.02266-10).
- Padrick SB, Miranker AD. 2002. Islet amyloid: phase partitioning and secondary nucleation are central to the mechanism of fibrillogenesis. *Biochemistry* **41**:4694–4703 DOI [10.1021/bi0160462](https://doi.org/10.1021/bi0160462).
- Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. 1996. HIV-1 dynamics *in vivo*: virion clearance rate, infected cell life-span, and viral generation time. *Science* **271**:1582–1586 DOI [10.1126/science.271.5255.1582](https://doi.org/10.1126/science.271.5255.1582).
- Pronchik J, He XL, Giurleo JT, Talaga DS. 2010. *In vitro* formation of amyloid from alpha-synuclein is dominated by reactions at hydrophobic interfaces. *Journal of American Chemical Society* **132**:9797–9803 DOI [10.1021/ja102896h](https://doi.org/10.1021/ja102896h).
- Rajan RS, Illing ME, Bence NF, Kopito RR. 2001. Specificity in intracellular protein aggregation and inclusion body formation. *Proceedings of the National Academy of Sciences of the United States of America* **98**:13060–13065 DOI [10.1073/pnas.181479798](https://doi.org/10.1073/pnas.181479798).
- Roan NR, Muller JA, Liu HC, Chu S, Arnold F, Sturzel CM, Walther P, Dong M, Witkowska HE, Kirchhoff F, Munch J, Greene WC. 2011. Peptides released by physiological cleavage of semen coagulum proteins form amyloids that enhance HIV Infection. *Cell Host & Microbe* **10**:541–550 DOI [10.1016/j.chom.2011.10.010](https://doi.org/10.1016/j.chom.2011.10.010).
- Roan NR, Munch J, Arhel N, Mothes W, Neidleman J, Kobayashi A, Smith-McCune K, Kirchhoff F, Greene WC. 2009. The cationic properties of SEVI underlie its ability to enhance human immunodeficiency virus infection. *Journal of Virology* **83**:73–80 DOI [10.1128/JVI.01366-08](https://doi.org/10.1128/JVI.01366-08).

- Roan NR, Sowinski S, Munch J, Kirchhoff F, Greene WC. 2010. Aminoquinoline surfen inhibits the action of SEVI (Semen-derived Enhancer of Viral Infection). *Journal of Biological Chemistry* 285:1861–1869 DOI 10.1074/jbc.M109.066167.
- Sawaya MR, Sambashivan S, Nelson R, Ivanova MI, Sievers SA, Apostol MI, Thompson MJ, Balbirnie M, Wiltzius JJW, McFarlane HT, Madsen AO, Riekel C, Eisenberg D. 2007. Atomic structures of amyloid cross-beta spines reveal varied steric zippers. *Nature* 447:453–457 DOI 10.1038/nature05695.
- Siddiqua A, Luo Y, Meyer V, Swanson MA, Yu X, Wei GH, Zheng J, Eaton GR, Ma BY, Nussinov R, Eaton SS, Margittai M. 2012. Conformational Basis for asymmetric seeding barrier in filaments of three- and four-repeat tau. *Journal of American Chemical Society* 134:10271–10278 DOI 10.1021/ja303498q.
- Suzuki Y, Brender JR, Hartman K, Ramamoorthy A, Marsh EN. 2012. Alternative pathways of human islet amyloid polypeptide aggregation distinguished by <sup>19</sup>F nuclear magnetic resonance-detected kinetics of monomer consumption. *Biochemistry* 51:8154–8162 DOI 10.1021/bi3012548.
- Thomas JA, Ott DE, Gorelick RJ. 2007. Efficiency of human immunodeficiency virus type 1 postentry infection processes: evidence against disproportionate numbers of defective virions. *Journal of Virology* 81:4367–4370 DOI 10.1128/JVI.02357-06.
- Thurman AR, Doncel GF. 2010. Innate immunity and inflammatory response to trichomonas vaginalis and bacterial vaginosis: relationship to HIV acquisition. *American Journal of Reproductive Immunology* 65:89–98 DOI 10.1111/j.1600-0897.2010.00902.x.
- Tukel C, Wilson RP, Nishimori JH, Pezeshki M, Chromy BA, Baumler AJ. 2009. Responses to amyloids of microbial and host origin are mediated through toll-like receptor 2. *Cell Host Microbe* 6:45–53 DOI 10.1016/j.chom.2009.05.020.
- Wang X, Hammer ND, Chapman MR. 2008. The molecular basis of functional bacterial amyloid polymerization and nucleation. *Journal of Biological Chemistry* 283:21530–21539 DOI 10.1074/jbc.M800466200.
- Wang XA, Smith DR, Jones JW, Chapman MR. 2007. *In vitro* polymerization of a functional Escherichia coli amyloid protein. *Journal of Biological Chemistry* 282:3713–3719 DOI 10.1074/jbc.M609228200.
- Wasmer C, Zimmer A, Sabate R, Soragni A, Saupe SJ, Ritter C, Meier BH. 2010. Structural similarity between the prion domain of HET-s and a homologue can explain amyloid cross-seeding in spite of limited sequence identity. *Journal of Molecular Biology* 402:311–325 DOI 10.1016/j.jmb.2010.06.053.
- Westermarck P, Lundmark K, Westermarck GT. 2009. Fibrils from designed non-amyloid-related synthetic peptides induce aa-amyloidosis during inflammation in an animal model. *PLOS ONE* 4:e6041 DOI 10.1371/journal.pone.0006041.
- Wiltzius JJW, Landau M, Nelson R, Sawaya MR, Apostol MI, Goldschmidt L, Soriaga AB, Cascio D, Rajashankar K, Eisenberg D. 2009. Molecular mechanisms for protein-encoded inheritance. *Nature of Structural Molecular Biology* 16:973–U998 DOI 10.1038/nsmb.1643.
- Wurm M, Schambach A, Lindemann D, Hanenberg H, Standker L, Forssmann WG, Blasczyk R, Horn PA. 2010. The influence of semen-derived enhancer of virus infection on the efficiency of retroviral gene transfer. *Journal of General Medicine* 12:137–146.

- Xue WF, Homans SW, Radford SE. 2008.** Systematic analysis of nucleation-dependent polymerization reveals new insights into the mechanism of amyloid self-assembly. *Proceedings of the National Academy of Sciences of the United States of America* **105**:8926–8931 DOI [10.1073/pnas.0711664105](https://doi.org/10.1073/pnas.0711664105).
- Yagi H, Kusaka E, Hongo K, Mizobata T, Kawata Y. 2005.** Amyloid fibril formation of alpha-synuclein is accelerated by preformed amyloid seeds of other proteins - Implications for the mechanism of transmissible conformational diseases. *Journal of Biological Chemistry* **280**:38609–38616 DOI [10.1074/jbc.M508623200](https://doi.org/10.1074/jbc.M508623200).
- Ye ZQ, French KC, Popova LA, Lednev IK, Lopez MM, Makhatadze GI. 2009.** Mechanism of fibril formation by a 39-Residue Peptide (PAPf39) from human prostatic acidic phosphatase. *Biochemistry* **48**:11582–11591 DOI [10.1021/bi901709j](https://doi.org/10.1021/bi901709j).
- Yin J, Chen RZ, Liu CL. 2009.** Nucleic acid induced protein aggregation and its role in biology and pathology. *Frontiers in Bioscience* **14**:5084–5106 DOI [10.2741/3588](https://doi.org/10.2741/3588).
- Yu X, Luo Y, Dinkel P, Zheng J, Wei GH, Margittai M, Nussinov R, Ma BY. 2012.** Cross-seeding and conformational selection between three- and four-repeat human tau proteins. *Journal of Biology Chemistry* **287**:14950–14959 DOI [10.1074/jbc.M112.340794](https://doi.org/10.1074/jbc.M112.340794).